Latest in Lipidology
Ongoing surveillance of the clinical lipidology literature, regulatory actions, and guideline developments relevant to the practice of this clinic. Each entry summarizes primary sources and links to them directly.
These summaries are provided for clinical decision support only and do not replace individualized clinical judgment or review of the primary literature.
Table of contents
- PCSK9 inhibitors lower LDL after a heart transplant, but the graft benefit is unproven (2026-08-30)
- When Lp(a) is high, a standard apoB result understates the risk (2026-08-30)
- Lp(a) treatment is now being tested in people who have not yet had a heart attack (2026-08-23)
- Two out of three people having a first heart attack were not on a statin (2026-08-20)
- Europe and America now agree on why cholesterol matters. They still differ on how to act on it. (2026-08-20)
- The first PCSK9 pill is approved. The outcome trial is still running. (2026-08-20)